Keeping the Grim Reaper at Bay
Once lung cancer moves beyond its original site, the prognosis dims. Researchers have discovered that a specific test can be used to identify patients who will benefit from different types of therapy - a finding that offers more personalized care for advanced lung cancer patients.
Higher Does Not Mean Longer
Radiation oncologists believed that a higher dosage of radiation would extend the lives of patients with advanced lung cancer. It seemed logical, but the findings of a clinical trial don't support that logic.
New Test Detects Treatable Lung Cancer Gene
Days after receiving U.S. Food and Drug Administration (FDA) approval, the Abbott ALK test for non-small-cell lung cancer (NSCLC) has become available in the United States, European Union and New Zealand.
FDA Approves Xalkori and Vysis ALK Break Apart FISH Probe Kit
The U.S. Food and Drug Administration today approved Xalkori ( crizotinib ) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers ( NSCLC ) who express the abnormal anaplastic lymphoma kinase ( ALK ) gene.
Doubling Progression-Free Survival
Being diagnosed with lung cancer usually means months of chemotherapy followed by a relapse. That outlook is changing for the better.
Slowing Advanced Lung Cancer
Advanced lung cancer offers few options for patients, unfortunately. A recent Spanish study opens new possibilities by extending the use of an established treatment drug, Alimta.
Diagnosing Smoke-Less Lung Cancer
While smokers are the largest group of people diagnosed with lung cancer, surpirsingly individuals who have never smoked tobacco make up one quarter of all victims.